Acquisition of Atlean from GSK Stiefel

Sinclair IS Pharma plc

Acquisition of Atlean® from GSK Stiefel

London, 31st January 2014 - Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair" or "the Group"), the international specialty pharmaceutical company, announces that it has acquired Atlean®, a dermal filler, from Stiefel the dermatology business of GSK for an undisclosed cash consideration. Atlean® combines a collagen stimulator and hyaluronic acid filler particularly for the treatment of the lower face and complements Sinclair's existing facial aesthetic brands, Sculptra® and Perfectha®. This acquisition enables Sinclair to add a collagen stimulator to market alongside Perfectha® in its international facial aesthetics business focused on Asia-Pacific, LATAM and Russia. In Europe Atlean® will provide Sinclair's aesthetic sales forces with a yet more comprehensive product range.

Atlean® has not been actively marketed in Europe since 2012 and requires the European CE Mark registration to be regained which is expected to take around 9-12 months. First revenues are therefore expected in H2 FY2015.

Ends

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Robert Taylor

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

Notes to Editors:

About Sinclair IS Pharma plc - see www.sinclairispharma.com 

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular - Aesthetics, Wound care, and Skin care. The Group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.